Showing 6631-6640 of 8280 results for "".
- Online Booking Functionality Comes to Demandforcehttps://practicaldermatology.com/news/online-booking-functionality-comes-to-demandforce/2460615/Demandforce has launched Demandforce Online Booking, a new functionality that makes it easier for clients of Demandforce business users to schedule appointments online while enabling businesses to manage their appointment sche
- Research Identifies Long-Term Benefits of Incorporating Ceramides into Baby Skincarehttps://practicaldermatology.com/news/research-identifies-long-term-benefits-of-incorporating-ceramides-into-baby-skincare/2460612/Using ceramide-infused products on baby skin may have long-term benefits lasting into adulthood, according to a newly published study in the Journal of Drugs in Dermatology. Beyond n
- Telemedicine Slashes Dermatology Consult Time from 84 Days to 5 Hourshttps://practicaldermatology.com/news/telemedicine-slashes-dermatology-consult-time-from-84-days-to-5-hours/2460609/When patients’ primary care doctors were able to photograph areas of concern and share them with dermatologists, the response time for a consultation dropped from almost 84 days to under five hours, finds a new study from researchers in the Perelman School of Medicine at the Unive
- Study: “Baby Botox” Boosts Skin Texture, Shrinks Poreshttps://practicaldermatology.com/news/study-baby-botox-boosts-skin-texture-shrinks-pores/2460603/Using many tiny doses of botulinum toxin injected in a grid pattern just under the surface of the facial skin may improve skin texture and roughness, according to a
- Tremfya Reduces Fatigue in PsAhttps://practicaldermatology.com/news/tremfya-reduces-fatigue-in-psa/2460602/The IL-23 blocker Tremfya (guselkumab) improves fatigue in adult patients with active psoriatic arthritis (PsA) and this response is maintained through 52 weeks of active treatment, according to data from two Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2. Tremfya improved
- Cosentyx Shows Early Synovitis Reduction in PsAhttps://practicaldermatology.com/news/cosentyx-shows-early-synovitis-reduction-in-psa/2460600/Cosentyx (secukinumab) showed early reduction of synovitis in psoriatic arthritis (PsA), according to the Phase IIIb ULTIMATE trial which will be presented at the American College of Rheumatology (ACR) All-Virtual Annual Meeting. Specifically, a significant reduction of synovitis&n
- Cutera Gives Back: Company Donates Tattoo Removal Laser to Gang Rehabilitation and Re-entry Programhttps://practicaldermatology.com/news/cutera-gives-back-company-donates-tattoo-removal-laser-to-gang-rehabilitation-and-re-entry-program/2460597/Cutera, Inc. is donating an enlighten tatoo removal laser along with clinical training and service to Homeboy Industries, a gang rehabilitation and re-entry program in Los Angeles. Homeboy Industries provides parenting classes, anger management and tattoo removal to support former
- Ilumya Shows 5-Year Sustained Efficacy and Safety in Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/ilumya-shows-5-year-sustained-efficacy-and-safety-in-moderate-to-severe-plaque-psoriasis/2460596/Patients with moderate-to-severe plaque psoriasis who continued to receive Ilumya (tildrakizumab-asmn) through five years of continuous treatment maintained consistent and extensive skin clearance with no new safety signals, according to Phase 3 data from the combined reSURFACE 1 and reSURFACE 2
- New Bimekizumab Phase 3 Data Presented at EADVhttps://practicaldermatology.com/news/new-bimekizumab-phase-3-data-presented-at-eadv/2460594/UCB shared detailed results of the head-to-head Phase 3 BE SURE study, which demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved superior skin clearance, as compared to adalimumab, in adults with moderate to severe plaque psoriasis. These findi
- Soliton Names New President and CEOhttps://practicaldermatology.com/news/soliton-names-new-president-and-ceo/2460593/Brad A. Hauser is the new President and Chief Executive Officer of Soliton. He most recently served as Vice President, R&D and General Manager for CoolSculpting at Allergan Aesthetics, an AbbVie Company, since Allergan's April 2017